BiotechTube

Dimebon (latrepirdine)

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington Disease

Conditions

Huntington Disease

Trial Timeline

Feb 1, 2010 → —

NCT ID
NCT01085266

About Dimebon (latrepirdine)

Dimebon (latrepirdine) is a phase 3 stage product being developed by Pfizer for Huntington Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01085266. Target conditions include Huntington Disease.

What happened to similar drugs?

1 of 10 similar drugs in Huntington Disease were approved

Approved (1) Terminated (1) Active (8)
✅TetrabenazineLundbeckApproved
🔄Votoplam (blinded) + PlaceboNovartisPhase 3
🔄RO7234292 (RG6042)RochePhase 3
🔄RO7234292 + PlaceboRochePhase 3
🔄DimebonPfizerPhase 3
🔄RiluzoleSanofiPhase 3
🔄ValbenazineNeurocrine BiosciencesPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01085266Phase 3Terminated

Competing Products

20 competing products in Huntington Disease

See all competitors
ProductCompanyStageHype Score
atomoxetine + Matching PlaceboEli LillyPhase 2
35
Votoplam (blinded) + PlaceboNovartisPhase 3
47
VotoplamNovartisPhase 2
39
Branaplam + PlaceboNovartisPhase 2
27
AFQ056 + PlaceboNovartisPhase 2
27
RO7234292 (RG6042)RochePhase 1
29
Tominersen + PlaceboRochePhase 2
39
RO7234292 (RG6042)RochePhase 3
40
RO7234292 (RG6042)RochePhase 2
35
RG6496 + PlaceboRochePhase 1
36
RO7234292 + PlaceboRochePhase 3
40
PF-02545920 + PF-02545920PfizerPhase 2
35
Dextromethorphan + Dimebon + DextromethorphanPfizerPhase 1
29
DimebonPfizerPhase 3
40
20 mg BID of PF-02545920PfizerPhase 2
27
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
35
RiluzoleSanofiPhase 3
40
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
33
TetrabenazineLundbeckApproved
36
ValbenazineNeurocrine BiosciencesPhase 3
41